Microbot Medical Inc. - Common Stock (MBOT)

EQNX::TICKER_START (NYSE:KULR),(NASDAQ:CHRW),(NYSE:PBI),(NYSE:GXO),(NASDAQ:MBOT) EQNX::TICKER_END

Successful robotic navigation was achieved in every case and met the primary endpoint of the study

PALM BEACH, Fla., April 15, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts project that the wearable robotic exoskeleton market, which has experienced notable growth over the past decade, driven by advancements in robotics, the increasing need for rehabilitation technologies, and heightened emphasis on workplace safety, will continue to grow substantially. The market’s growth has been particularly robust in the healthcare and manufacturing sectors, where both assistive and powered exoskeletons are in high demand. Furthermore, the market’s expansion is propelled by technological innovations, with powered systems holding the largest wearable robotic exoskeleton market share due to their superior performance and adaptability. Ongoing technological advancements, particularly in AI, sensors, and battery efficiency, are expected to drive further adoption across various sectors. The healthcare sector is anticipated to witness increased adoption of rehabilitation and assistive solutions. At the same time, the defense and manufacturing industries continue to seek solutions for enhancing human endurance and reducing injury risks. With strong growth projections, especially in emerging markets such as Asia Pacific, the market is expected to see continued investment and development over the forecast period. A report from Fortune Business Insights said that the global wearable robotic exoskeleton market size is projected to grow to USD 30.56 billion by 2032, exhibiting a CAGR of 43.1% during the forecast period. North America dominated the global market with a share of 38.64% in 2024. Active companies in news today include: KULR Technology Group, Inc. (NYSE: KULR), C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW), Pitney Bowes (NYSE: PBI), GXO Logistics, Inc. (NYSE: GXO), Microbot Medical Inc. (NASDAQ: MBOT).

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year

Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation model

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company’s authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the series I preferred investment options and the shares issuable upon exercise thereof.

BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company’s authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions.

Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics

Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization

Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter.

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about January 9, 2025, subject to the satisfaction of customary closing conditions.

HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,002 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter.

HINGHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,004 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.

Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025

Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live

FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial

EQNX::TICKER_START (NASDAQ:JFBR),(NASDAQ:SERV),(NASDAQ:SYM),(NASDAQ:MBOT),(NYSE:MDT) EQNX::TICKER_END

PALM BEACH, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence, machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: “The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence.” Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024

Confirms the Company on Track for FDA 510(k) Submission by end of 2024

Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024

The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform

The ISO 13485 certification is a validation of the Company’s robust quality system